Health 2.0 Europe 2016

11 - 12 May 2016, Barcelona, Spain.
The 7th edition of Health 2.0 Europe is coming back to Barcelona for 3 full days of content that will explore European and international innovation in patient-provider communication, consumer health, data analytics and more.

Over 120 speakers and 600 attendees from around the world will reconvene to experience over 50 live product demos of innovative solutions that will shake up European health systems.

Confirmed keynotes already include:

  • Esther Dyson, Chairman, EDventure Holdings (USA)
  • Dr. Rafael Grossmann, Practicing surgeon and digital health pionneer (USA)
  • Damien Marmion, Global Head of Health, AXA (France)
  • Dr. Julio Mayol, Director of Innovation, Hospital Clinico San Carlos (Spain)
  • Pēteris Zilgalvis, Head of Unit, eHealth and Well Being – DG CONNECT, European Commission (Belgium)

Confirmed digital health champions also include:

  • Artem Andrianov, CEO, Cyntegrity (Germany)
  • Jani Ahonala, Co-founder & Chairman of the Board, Noona Healthcare, (Finland)
  • Dr. Tom Albert, Director - Health Strategy, AXA Krankenversicherung AG (Germany)
  • Jordina Arcal, Co-founder & COO, HealthApp (Spain)
  • Dr. Alexander Börve, Founder and CEO, FirstDerm.com (Sweden/USA)
  • Vas Bailey, Principal, Quid, Inc (USA)
  • Vedran Boškić, Healthcare ICT consultant, Parsek (Slovenia)
  • Joan Cornet, mHealth Director, Mobile World Capital (Spain)
  • Dustin DiTommaso, SVP, Behavior Change Design, Mad*Pow (USA)
  • Dr. Eduardo García Cruz, Urologist and Men’s Health Specialist, Barcelona Hospital Clinic (Spain)
  • Jorge Gonzalez, Managing Director, TICBioMed (Spain)
  • Jamison Feramisco, President and Co-Founder, Transfuse Solutions, Inc. (USA)
  • Tal Givoly, CEO and Co-founder, Medivizor (Israel)
  • Jorge Gonzalez Olalla, Managing Director, TICBioMed (Spain)
  • Min-Sung Sean Kim, Partner, XL Health (Germany)
  • Jörg Land, CEO, Tinnitracks (Germany)
  • Robert Milnes, CEO, Fertility Focus Limited (United Kingdom)
  • Peter Ohnemus, President & CEO, Dacadoo (Switzerland)
  • Pablo Pantaleoni, CEO, MedTep (Spain/USA)
  • Michael Seres, Founder, 11Health (United Kingdom)
  • Dr. Alexander Schachinger, CEO, EPatient RSD (Germany)
  • Mitchell Silva, Founder and CEO, Esperity (Belgium)
  • Marta Sjögren, Principal, Northzone (Sweden)
  • Pierre Socha, Investment Manager, Amadeus Capital Partners (United Kingdom)
  • Ed Stafford, Director of Informatics, Genomics England (United Kingdom)
  • Unity Stoakes, ‎Co-founder and President, StartUp Health (USA)
  • Donato Tramuto, President and CEO, Healthways and Founder, Health eVillages, (USA)
  • Salvador Vera, CEO, MYSPHERA (Spain)
  • Frank Westermann, Co-founder and CEO, mysugr (Austria)

A mix of visionary keynotes and interactive panel discussions, the 2016 edition will cover some of the following overarching themes:

  • Building blocks to a dynamic health innovation ecosystem
  • Data analytics: Structuring information for decision making
  • Solutions for hospitals and health professionals
  • Gamification and design strategies for behaviour change
  • Pharma 2.0: Going beyond the pill
  • Who will pay for Health 2.0?
  • Reimbursement - Players, trends, criteria and processes
  • The rise of consumer health interfaces
  • "SHUSH topics" and the infamous Unmentionables
  • Health 2.0 applications in emerging markets

For further information and to register, please visit:
https://goo.gl/IVCb3P

PS: Get 15% discount to attend Health 2.0 Europe 2016 using the code EHNEWS16

About Health 2.0
Health 2.0 is the premiere showcase and catalyst for the advancement of new health technologies. Through a global series of conferences, developer competitions, and leading market intelligence, Health 2.0 drives the innovation and collaboration necessary to transform health and health care. In addition to our flagship event held in the Bay Area each Fall, we host events around the world including in Europe, Latin America and India, and new for 2015 Korea and Japan.

Most Popular Now

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

A soybean protein blocks LDL cholesterol productio…

A protein in soybeans blocks the production of a liver enzyme involved in the metabolism of triglycerides and low-density lipoprotein, scientists found in a recent study...

Discovery of anti-cancer chemistry makes skullcap …

The evolutionary secrets that enable the medicinal herb known as barbed skullcap to produce cancer fighting compounds have been unlocked by a collaboration of UK and Chin...